Key Segments:
By Technology
-
ADAR-Mediated Editing
-
APOBEC-Mediated Editing
-
Others
By Delivery Modality
-
Oligonucleotide-Based
-
AAV-Delivered
-
Lipid Nanoparticle-Delivered
-
Others
By Application
-
Rare Genetic Disorders
-
Oncology
-
Neurological Disorders
-
Liver and Cardiometabolic Disorders
-
Others
By End Use
-
Pharmaceutical and Biotechnology Companies
-
Academic and Research Institutes
-
Contract Research and Development Organizations
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market includes Wave Life Sciences, ProQR Therapeutics, Korro Bio, Shape Therapeutics, Ascidian Therapeutics, AIRNA, Rznomics, Amber Bio and Tacit Therapeutics, among others. These companies compete on editing chemistry, delivery modality, clinical stage and pharmaceutical partnership activity.
The main opportunities lie in extending RNA editing platforms into cardiometabolic, kidney and neurological indications, licensing platforms to large pharmaceutical companies, and serving the large population of rare disease patients who still lack an approved disease-modifying treatment.
The key growth factor is expanding clinical validation of RNA editing chemistries combined with a large underserved rare and genetic disease population, which together are drawing increasing pharmaceutical licensing and investor capital into the sector.
By technology, the ADAR-Mediated Editing segment dominated the market with approximately 76.95% share in 2025, supported by its use of native human enzymes and the deepest base of clinical data among current editing chemistries.
North America dominated the market with approximately 57.64% share in 2025, supported by its concentration of clinical-stage developers and specialized venture capital. Asia Pacific is the fastest-growing region with a projected CAGR of 21.15% from 2026 to 2035.
